Should the FDA's criteria for the clinical efficacy of cachexia drugs be changed? Is Ostarine safe and effective?
作者信息
Lambert Charles Paul
机构信息
University of California, San Diego, San Diego, CA, USA.
出版信息
J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):531-532. doi: 10.1002/jcsm.12695. Epub 2021 Mar 23.
Abstract
摘要
相似文献
1
Should the FDA's criteria for the clinical efficacy of cachexia drugs be changed? Is Ostarine safe and effective?美国食品药品监督管理局（FDA）关于恶病质药物临床疗效的标准应该改变吗？奥司他丁安全有效吗？
J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):531-532. doi: 10.1002/jcsm.12695. Epub 2021 Mar 23.
2
3
FDA's classification of new drugs.美国食品药品监督管理局对新药的分类。
N Engl J Med. 1980 Jun 12;302(24):1368-9.
4
The FDA's classification system for new drugs. An evaluation of therapeutic gain.美国食品药品监督管理局的新药分类系统。治疗收益评估。
N Engl J Med. 1980 Jan 17;302(3):181-3. doi: 10.1056/NEJM198001173020322.
5
The FDA's new drug rating system.美国食品药品监督管理局的新药评级系统。
Ohio Med. 1991 Mar;87(3):133-4.
6
Understanding the FDA's guarded system for classifying new drugs.了解美国食品药品监督管理局（FDA）对新药进行分类的谨慎系统。
Hosp Pharm. 1979 May;14(5):262-4, 266, 268 passim.
7
FDA's role in responding to drug shortages.美国食品药品监督管理局在应对药品短缺方面的作用。
Am J Health Syst Pharm. 2002 Aug 1;59(15):1423-5. doi: 10.1093/ajhp/59.15.1423.
8
FDA's biomedical research program.美国食品药品监督管理局的生物医学研究项目。
J Parenter Drug Assoc. 1980 Mar-Apr;34(2):134-8.
9
FDA's safety reform is greeted with scepticism.美国食品药品监督管理局的安全改革受到质疑。
BMJ. 2005 Feb 26;330(7489):435. doi: 10.1136/bmj.330.7489.435.
10
FDA's New Guidance for Industry Addressing Evaluation of the Safety of New Drugs for Improving Glycemic Control: A Case Study in Regulatory Science.美国食品药品监督管理局（FDA）关于评估改善血糖控制新药安全性的行业新指南：监管科学案例研究
Ther Innov Regul Sci. 2021 Jan;55(1):1-5. doi: 10.1007/s43441-020-00211-6.
引用本文的文献
1
Ostarine blunts the effect of endurance training on submaximal endurance in rats.Ostarine 削弱了耐力训练对大鼠亚极量耐力的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6523-6532. doi: 10.1007/s00210-024-03030-w. Epub 2024 Mar 7.
2
Selective Androgen Receptor Modulators Combined with Treadmill Exercise Have No Bone Benefit in Healthy Adult Rats.选择性雄激素受体调节剂联合跑步机运动对健康成年大鼠无骨骼益处。
Pharmaceuticals (Basel). 2023 Sep 5;16(9):1249. doi: 10.3390/ph16091249.
3
Considerations for designing trials targeting muscle dysfunction in exercise oncology.运动肿瘤学中针对肌肉功能障碍的试验设计考量
Front Physiol. 2023 Feb 9;14:1120223. doi: 10.3389/fphys.2023.1120223. eCollection 2023.
4
Selective Androgen Receptor Modulators: An Emerging Liver Toxin.选择性雄激素受体调节剂：一种新兴的肝毒素。
J Clin Transl Hepatol. 2023 Feb 28;11(1):188-196. doi: 10.14218/JCTH.2022.00207. Epub 2022 Nov 4.
5
Inflammation as a Therapeutic Target in Cancer Cachexia.炎症作为癌症恶病质的治疗靶点。
Cancers (Basel). 2022 Oct 26;14(21):5262. doi: 10.3390/cancers14215262.
本文引用的文献
1
Elevated Inflammatory Status and Increased Risk of Chronic Disease in Chronological Aging: Inflamm-aging or ?自然衰老过程中炎症状态升高与慢性病风险增加：炎症衰老还是其他？
Aging Dis. 2019 Feb 1;10(1):147-156. doi: 10.14336/AD.2018.0326. eCollection 2019 Feb.
2
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).选择性雄激素受体调节剂恩杂鲁胺用于预防和治疗癌症患者肌肉萎缩的3期临床开发项目（POWER试验）的研究设计与原理
Curr Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0.
3
Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014.恶病质的流行率、发生率和临床影响：事实和数据更新 2014 年版。
J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):261-3. doi: 10.1007/s13539-014-0164-8.
4
Effects of aging and resistance exercise on determinants of muscle strength.衰老及抗阻运动对肌肉力量决定因素的影响。
J Am Aging Assoc. 2002 Apr;25(2):73-8. doi: 10.1007/s11357-002-0005-0.
5
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.依诺羟司他对癌症患者肌肉减少症及身体机能的影响：一项双盲、随机对照 2 期试验。
Lancet Oncol. 2013 Apr;14(4):335-45. doi: 10.1016/S1470-2045(13)70055-X. Epub 2013 Mar 14.
6
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.选择性雄激素受体调节剂GTx-024（恩杂鲁胺）可改善健康老年男性和绝经后女性的瘦体重及身体功能：一项双盲、安慰剂对照II期试验的结果
J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-161. doi: 10.1007/s13539-011-0034-6. Epub 2011 Aug 2.
7
Exercise training and nutritional supplementation for physical frailty in very elderly people.针对高龄老人身体虚弱的运动训练与营养补充
N Engl J Med. 1994 Jun 23;330(25):1769-75. doi: 10.1056/NEJM199406233302501.
8
Neural adaptation to resistance training.神经对阻力训练的适应性
Med Sci Sports Exerc. 1988 Oct;20(5 Suppl):S135-45. doi: 10.1249/00005768-198810001-00009.
Zotero 插件